We are live on ! Find out more

Prime Medicine

PRME

Market cap $707M

3.90 USD

+0.40

11.43%

At close Updated Oct 7, 4:00 PM EDT

Pre-market

After hours

3.75

-0.15

3.85%

1 day

11.43%

5 days

27.87%

1 month

9.55%

3 months

-2.26%

6 months

14.37%

Year to date

10.48%

1 year

-33.56%

5 years

-74.63%

10 years

-74.63%

About: Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Employees: 146

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35.7%

Neutral 57.1%

Negative 7.1%

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most prevalent Wilson disease-causing mutation in North America and Europe‌ --

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement

Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. PM359 is positioned for a potential BLA submission for CGD in 1H 2027, leveraging RMAT and other regulatory designations. Initial clinical data from global phase 1/2 studies of PM577a [WD] and PM647 [AATD] are expected in 2027, targeting significant market opportunities.

Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement

Prime Medicine Gets FDA Green Light for Gene Editing Study

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology firm developing one-time curative genetic therapies, announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for PM647.

Prime Medicine Gets FDA Green Light for Gene Editing Study

Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Tamboran Resources Corp. (NYSE:TBN) to post a quarterly loss of 30 cents per share on revenue of $3.82 million before the opening bell, according to data from Benzinga Pro. Tamboran Resources shares gained 1.4% to close at $36.25 on Thursday.

Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

-- Clearance highlights continued execution, modularity and momentum across Prime Medicine's liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected in 2027 --

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: Wells Fargo 21st Annual Healthcare Conference: Company management will host 1x1 meetings on Thursday, September 10, 2026, in Boston, MA.

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine: Soon In The Clinic

Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-in-class gene-editing pipeline. PRME's therapies target five indications across liver, lung, and immunology/oncology, with leading preclinical efficacy and multi-billion-dollar addressable markets. Recent IND/CTA clearances, RMAT designation, and patent wins highlight PRME's clinical and strategic momentum despite a 54% stock decline from 52-week highs.

Prime Medicine: Soon In The Clinic

Zacks Investment Research

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research

Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

See News Rankings

Price charts implemented using Lightweight Charts™